Bibliography



Bibliography

Allen B, Mato JM, Craig A, Fernandez-Ramos D, Lopitz-Otsoa F, Hayardeny L, Villanueva A and Friedman SL. (2018). Aramchol Downregulates SCD1 and Induces PPARγ in Hepatic Stellate Cells to Attenuate Cellular Activation and Fibrogenesis.

Almeida AS, Soares NL, Vieira M, Gramsbergen JB and Vieira HL. (2016). Carbon Monoxide Releasing Molecule-A1 (CORM-A1) improves neurogenesis: increase of neuronal differentiation yield by preventing cell death. *PloS one* 11:e0154781.

Alves-Paiva RM, Kajigaya S, Feng X, Chen J, Desierto M, Wong S, Townsley DM, Donaires FS, Bertola A and Gao B. (2018). Telomerase enzyme deficiency promotes metabolic dysfunction in murine hepatocytes upon dietary stress. *Liver International* 38:144-154.

Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL and NAFLD1 APWPo. (2007). How common is non-alcoholic fatty liver disease in the Asia–Pacific region and are there local differences? *Journal of gastroenterology and hepatology* 22:788-793.

Anstee QM and Day CP. (2015). The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. In: Editior, editor^editors. Seminars in liver disease. Thieme Medical Publishers, 270-290.

Anstee QM, Targher G and Day CP. (2013). Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature reviews Gastroenterology & hepatology* 10:330.

Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K and Morita K. (2012). Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. *Translational Research* 159:25-31.

Asrani SK, Devarbhavi H, Eaton J and Kamath PS. (2018). Burden of liver diseases in the world. *Journal of hepatology*.

Auger C, Alhasawi A, Contavadoo M and Appanna VD. (2015). Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders. *Frontiers in cell and developmental biology* 3:40.

Beckman JD, Belcher JD, Vineyard JV, Chen C, Nguyen J, Nwaneri MO, O'Sullivan MG, Gulbahce E, Hebbel RP and Vercellotti GM. (2009). Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. *American Journal of Physiology-Heart and Circulatory Physiology* 297:H1243-H1253.

Beery RMM, Vaziri H and Forouhar F. (2014). Primary biliary cirrhosis and primary sclerosing cholangitis: a review featuring a women's health perspective. *Journal of clinical and translational hepatology* 2:266.

Begriche K, Igoudjil A, Pessayre D and Fromenty B. (2006). Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. *Mitochondrion* 6:1-28.

Bergamini CM, Gambetti S, Dondi A and Cervellati C. (2004). Oxygen, reactive oxygen species and tissue damage. *Current pharmaceutical design* 10:1611-1626.

Bernal W, Auzinger G, Dhawan A and Wendon J. (2010). Acute liver failure. *The Lancet* 376:190-201.

Bieghs V, Wouters K, Van Gorp PJ, Gijbels MJ, De Winther MP, Binder CJ, Lütjohann D, Febbraio M, Moore KJ and Van Bilsen M. (2010). Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. *Gastroenterology* 138:2477-2486. e2473.

Bjørndal B, Alterås EK, Lindquist C, Svardal A, Skorve J and Berge RK. (2018). Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice. *Nutrition & metabolism* 15:10.

Bloch KD, Ichinose F, Roberts Jr JD and Zapol WM. (2007). Inhaled NO as a therapeutic agent. *Cardiovascular research* 75:339-348.

Boczkowski J, Poderoso JJ and Motterlini R. (2006). CO–metal interaction: vital signaling from a lethal gas. *Trends in biochemical sciences* 31:614-621.

Boden-Albala B and Sacco RL. (2000). Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. *Current atherosclerosis reports* 2:160-166.

Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA and Yang CS. (2008). The major green tea polyphenol,(-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat–fed mice. *The Journal of nutrition* 138:1677-1683.

Boyer TD and Zakim D. (1990). Hepatology: a textbook of liver disease. WB Saunders.

Brookes PS. (2005). Mitochondrial H+ leak and ROS generation: an odd couple. *Free Radical Biology and Medicine* 38:12-23.

Brunt EM. (2005). Pathology of nonalcoholic steatohepatitis. *Hepatology Research* 33:68-71.

Buzzetti E, Pinzani M and Tsochatzis EA. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism* 65:1038-1048.

Carmiel-Haggai M, Cederbaum AI and Nieto N. (2005). A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. *The FASEB Journal* 19:136-138.

Carvalho NR, da Rosa EF, da Silva MH, Tassi CC, Dalla Corte CL, Carbajo-Pescador S, Mauriz JL, González-Gallego J and Soares FA. (2013). New therapeutic approach: diphenyl diselenide reduces mitochondrial dysfunction in acetaminophen-induced acute liver failure. *PLoS One* 8:e81961.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 142:1592-1609.

Chan HM and Cherian MG. (1992). Protective roles of metallothionein and glutathione in hepatotoxicity of cadmium. *Toxicology* 72:281-290.

Chang C-R and Blackstone C. (2010). Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. *Annals of the New York Academy of Sciences* 1201:34.

Chen B, Guo L, Fan C, Bolisetty S, Joseph R, Wright MM, Agarwal A and George JF. (2009). Carbon monoxide rescues heme oxygenase-1-deficient mice from arterial

thrombosis in allogeneic aortic transplantation. *The American journal of pathology* 175:422-429.

Cheng Y, Zhang K, Chen Y, Li Y, Li Y, Fu K and Feng R. (2016). Associations between dietary nutrient intakes and hepatic lipid contents in NAFLD patients quantified by 1H-MRS and dual-Echo MRI. *Nutrients* 8:527.

Chora ÂA, Fontoura P, Cunha A, Pais TF, Cardoso S, Ho PP, Lee LY, Sobel RA, Steinman L and Soares MP. (2007). Heme oxygenase–1 and carbon monoxide suppress autoimmune neuroinflammation. *The Journal of clinical investigation* 117:438-447.

Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, Foresti R and Motterlini R. (2003). Cardioprotective actions by a water-soluble carbon monoxide–releasing molecule. *Circulation research* 93:e2-e8.

ClinicalTrials.gov. (Record as of May 25, 2015a). Carbon monoxide therapy for severe pulmonary arterial hypertension (CO in PAH). Identifier: NCT01523548 First received: January 27, 2012; Last updated: April 1, 2015; Last verified: April 2015.

ClinicalTrials.gov. (Record as of May 25, 2015b). Carbon monoxide to prevent lung inflammation. Identifier: NCT00094406 First received: October 16, 2004; Last updated: May 20, 2015; Last verified: May 2015.

ClinicalTrials.gov. (Record as of May 25, 2015c). Safety study of inhaled carbon monoxide to treat acute respiratory distress syndrome (ARDS). Identifier: NCT02425579 First received: March 17, 2015; Last updated: August 21, 2015; Last verified: August 2015.

ClinicalTrials.gov. (Record as of May 25, 2015d). Study of inhaled carbon monoxide to treat idiopathic pulmonary fibrosis. Identifier: NCT01214187. First received: September 30, 2010; Last updated: May 11, 2015; Last verified: May 2015.

Cohen JC, Horton JD and Hobbs HH. (2011). Human fatty liver disease: old questions and new insights. *Science* 332:1519-1523.

Cortez-Pinto H, Chatham J, Chacko V, Arnold C, Rashid A and Diehl AM. (1999). Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. *Jama* 282:1659-1664.

Cortez-Pinto H, de Moura MC and Day CP. (2006). Non-alcoholic steatohepatitis: from cell biology to clinical practice. *Journal of hepatology* 44:197-208.

Cousin SP, Hügl SR, Wrede CE, Kajio H, Myers Jr MG and Rhodes CJ. (2001). Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic β-cell line INS-1. *Endocrinology* 142:229-240.

Cui W, Chen SL and Hu K-Q. (2010). Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. *American journal of translational research* 2:95.

Dabhi A, Brahmbhatt K, Pandya T, Thorat P and Shah M. (2008). Non-alcoholic fatty liver disease (NAFLD). *Journal Indian Academy of Clinical Medicine* 9:36-41.

Dambach DM, Durham SK, Laskin JD and Laskin DL. (2006). Distinct roles of NF-κB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. *Toxicology and applied pharmacology* 211:157-165.

Davies MJ. (1989). Detection of peroxyl and alkoxyl radicals produced by reaction of hydroperoxides with rat liver microsomal fractions. *Biochemical Journal* 257:603-606.

Day CP. (2010). Genetic and environmental susceptibility to non-alcoholic fatty liver disease. *Digestive diseases* 28:255-260.

Day CP and James OF. (1998). Steatohepatitis: a tale of two "hits"? In: Editior, editor^editors. Elsevier.

de Haan JB. (2011). Nrf2 activators as attractive therapeutics for diabetic nephropathy. *Diabetes* 60:2683-2684.

De Oliveira CPMS, Stefano JT, De Siqueira ERF, Silva LS, de Campos Mazo DF, Lima VMR, Furuya CK, Mello ES, Souza FG and Rabello F. (2008). Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. *Hepatology Research* 38:159-165.

Demaurex N and Distelhorst C. (2003). Cell biology. Apoptosis--the calcium connection. *Science* 300:65-67.

Dercho RA, Nakatsu K, Wong RJ, Stevenson DK and Vreman HJ. (2006). Determination of in vivo carbon monoxide production in laboratory animals via exhaled air. *Journal of pharmacological and toxicological methods* 54:288-295.

Di Pascoli M, Rodella L, Sacerdoti D, Bolognesi M, Turkseven S and Abraham NG. (2006). Chronic CO levels has a beneficial effect on vascular relaxation in diabetes. *Biochemical and biophysical research communications* 340:935-943.

Dinkova-Kostova AT and Abramov AY. (2015). The emerging role of Nrf2 in mitochondrial function. *Free Radical Biology and Medicine* 88:179-188.

Dong D, Xu L, Han X, Qi Y, Xu Y, Yin L, Liu K and Peng J. (2014). Effects of the total saponins from Rosa laevigata Michx fruit against acetaminophen-induced liver damage in mice via induction of autophagy and suppression of inflammation and apoptosis. *Molecules* 19:7189-7206.

Du K, McGill MR, Xie Y, Bajt ML and Jaeschke H. (2015). Resveratrol prevents protein nitration and release of endonucleases from mitochondria during acetaminophen hepatotoxicity. *Food and Chemical Toxicology* 81:62-70.

El-Lakkany NM, el-Din SHS, Sabra A-NA-A, Hammam OA and Ebeid FA-L. (2016). Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver. *Research in pharmaceutical sciences* 11:374.

Elizabeth LY, Golshan S, Harlow KE, Angeles JE, Durelle J, Goyal NP, Newton KP, Sawh MC, Hooker J and Sy EZ. (2019). Prevalence of nonalcoholic fatty liver disease in children with obesity. *The Journal of pediatrics* 207:64-70.

Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T and Yamamoto M. (2001). High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. *Toxicological Sciences* 59:169-177.

Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sanchez-Perez P, Cadenas S and Lamas S. (2015a). Antioxidant responses and cellular adjustments to oxidative stress. *Redox biology* 6:183-197.

Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sánchez-Pérez P, Cadenas S and Lamas S. (2015b). Antioxidant responses and cellular adjustments to oxidative stress. *Redox biology* 6:183-197.

Fagone P, Mangano K, Mammana S, Cavalli E, Di Marco R, Barcellona ML, Salvatorelli L, Magro G and Nicoletti F. (2015). Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats. *Clinical Immunology* 157:198-204.

Fagone P, Mangano K, Quattrocchi C, Motterlini R, Di Marco R, Magro G, Penacho N, Romao C and Nicoletti F. (2011). Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. *Clinical & Experimental Immunology* 163:368-374.

Faizan M, Muhammad N, Niazi KUK, Hu Y, Wang Y, Wu Y, Sun H, Liu R, Dong W and Zhang W. (2019). CO-Releasing Materials: An Emphasis on Therapeutic Implications, as Release and Subsequent Cytotoxicity Are the Part of Therapy. *Materials* 12:1643.

Fan J-G, Zhu J, Li X-J, Chen L, Li L, Dai F, Li F and Chen S-Y. (2005). Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. *Journal of hepatology* 43:508-514.

Ferrandiz M, Maicas N, Garcia-Arnandis I, Terencio M, Motterlini R, Devesa I, van den Berg W and Alcaraz M. (2008). Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis. *Annals of the rheumatic diseases* 67:1211-1217.

Fransen M, Nordgren M, Wang B and Apanasets O. (2012). Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1822:1363-1373.

Freitas A, Alves-Filho J, Secco D, Neto A, Ferreira S, Barja-Fidalgo C and Cunha F. (2006). Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. *British journal of pharmacology* 149:345-354.

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV and Craxi A. (2018). A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology* 67:1754-1767.

Fromenty B, Robin M, Igoudjil A, Mansouri A and Pessayre D. (2004). The ins and outs of mitochondrial dysfunction in NASH. *Diabetes & metabolism* 30:121-138.

Fu S, Watkins SM and Hotamisligil GS. (2012). The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. *Cell metabolism* 15:623-634.

Fuchs M and Sanyal AJ. (2012). Lipotoxicity in NASH. *Journal of hepatology* 56:291-293.

Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC and Farrell GC. (2014). Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. *Journal of hepatology* 61:1376-1384.

García-Ruiz I, Solís-Muñoz P, Fernández-Moreira D, Muñoz-Yagüe T and Solís-Herruzo JA. (2015). In vitro treatment of HepG2 cells with saturated fatty acids reproduces

mitochondrial dysfunction found in nonalcoholic steatohepatitis. *Disease models & mechanisms* 8:183-191.

Gujral JS, Knight TR, Farhood A, Bajt ML and Jaeschke H. (2002). Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? *Toxicological sciences* 67:322-328.

Han J and Kaufman RJ. (2016). The role of ER stress in lipid metabolism and lipotoxicity. *Journal of lipid research* 57:1329-1338.

Harrison S, Marri S, Chalasani N, Kohli R, Aronstein W, Thompson G, Irish W, Miles M, Xanthakos S and Lawitz E. (2016). Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. *Alimentary pharmacology & therapeutics* 44:1183-1198.

Heard K and Green J. (2012). Acetylcysteine therapy for acetaminophen poisoning. *Current pharmaceutical biotechnology* 13:1917-1923.

Hong X, Tang H, Wu L and Li L. (2006). Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. *Journal of Pharmacy and Pharmacology* 58:1391-1398.

Hosick PA, AlAmodi AA, Storm MV, Gousset MU, Pruett BE, Gray III W, Stout J and Stec DE. (2014). Chronic carbon monoxide treatment attenuates development of obesity and remodels adipocytes in mice fed a high-fat diet. *International journal of obesity* 38:132.

Ikenaga N, Peng Z-W, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, Mikels-Vigdal A, Smith V, Schuppan D and Popov YV. (2017). Selective targeting of lysyl oxidase-

like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. *Gut* 66:1697-1708.

Ikonen E. (2008). Cellular cholesterol trafficking and compartmentalization. *Nature reviews Molecular cell biology* 9:125.

Jadeja R, Devkar RV and Nammi S. (2014). Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. *Evidence-Based Complementary and Alternative Medicine* 2014.

Jadeja RN, Upadhyay KK, Devkar RV and Khurana S. (2016). Naturally occurring Nrf2 activators: potential in treatment of liver injury. *Oxidative medicine and cellular longevity* 2016.

Jadeja RN, Urrunaga NH, Dash S, Khurana S and Saxena NK. (2015). Withaferin-A reduces acetaminophen-induced liver injury in mice. *Biochemical pharmacology* 97:122-132.

Jaeschke H and Bajt ML. (2005). Intracellular signaling mechanisms of acetaminophen-induced liver cell death. *Toxicological sciences* 89:31-41.

Jaeschke H, McGill MR and Ramachandran A. (2012). Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. *Drug metabolism reviews* 44:88-106.

Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Ranvir R, Kadam S, Patel H and Swain P. (2018). Dual PPAR α/γ agonist Saroglitazar improves liver histopathology and biochemistry in experimental NASH models. *Liver International* 38:1084-1094.

James LP, McCullough SS, Lamps LW and Hinson JA. (2003). Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. *Toxicological sciences* 75:458-467.

Jaramillo MC and Zhang DD. (2013). The emerging role of the Nrf2-Keap1 signaling pathway in cancer. *Genes & development* 27:2179-2191.

Johnson TR, Mann BE, Clark JE, Foresti R, Green CJ and Motterlini R. (2003). Carbonylmetallkomplexe–eine neue Klasse von Pharmazeutika? *Angewandte Chemie* 115:3850-3858.

Jones Dt. (1986). Intracellular diffusion gradients of O2 and ATP. *American Journal of Physiology-Cell Physiology* 250:C663-C675.

Ju C. (2012). Damage-associated molecular patterns: Their impact on the liver and beyond during acetaminophen overdose. *Hepatology* 56:1599-1601.

Kaufman RJ. (2002). Orchestrating the unfolded protein response in health and disease. *The Journal of clinical investigation* 110:1389-1398.

Kerner J and Hoppel C. (2000). Fatty acid import into mitochondria. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* 1486:1-17.

Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, Chan B and Trudinger B. (2005). The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. *Annals of emergency medicine* 45:402-408.

Kim HJ, Joe Y, Kim S-K, Park S-U, Park J, Chen Y, Kim J, Ryu J, Cho GJ and Surh Y-J. (2017). Carbon monoxide protects against hepatic steatosis in mice by inducing

sestrin-2 via the PERK-eIF2α-ATF4 pathway. *Free Radical Biology and Medicine* 110:81-91.

Kitaoka Y, Takeda K, Tamura Y, Fujimaki S, Takemasa T and Hatta H. (2016). Nrf2 deficiency does not affect denervation-induced alterations in mitochondrial fission and fusion proteins in skeletal muscle. *Physiological reports* 4:e13064.

Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, Goldring CE, Powell H, Sanderson C and Williams S. (2010). Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. *Journal of proteomics* 73:1612-1631.

Knight TR, Ho Y-S, Farhood A and Jaeschke H. (2002). Peroxynitrite is a critical mediator of acetaminophen hepatotoxicity in murine livers: protection by glutathione. *Journal of Pharmacology and Experimental Therapeutics* 303:468-475.

Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K and Ustundag B. (2008). The treatment with antibody of TNF-α reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet. *Inflammation* 31:91-98.

Kovac S, Angelova PR, Holmström KM, Zhang Y, Dinkova-Kostova AT and Abramov AY. (2015). Nrf2 regulates ROS production by mitochondria and NADPH oxidase. *Biochimica et Biophysica Acta (BBA)-General Subjects* 1850:794-801.

Kowaltowski AJ and Vercesi AE. (1999). Mitochondrial damage induced by conditions of oxidative stress. *Free Radical Biology and Medicine* 26:463-471.

Kučera O, Endlicher R, Roušar T, Lotková H, Garnol T, Drahota Z and Červinková Z. (2014). The effect of tert-butyl hydroperoxide-induced oxidative stress on lean and steatotic rat hepatocytes in vitro. *Oxidative medicine and cellular longevity* 2014.

Kučera O, Garnol T, Lotková H, Staňková P, Mazurová Y, Hroch M, Bolehovská R, Roušar T and Červinková Z. (2011). The effect of rat strain, diet composition and feeding period on the development of a nutritional model of non-alcoholic fatty liver disease in rats. *Physiol Res* 60:317-328.

Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C and Sarin SK. (2013). Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? *Indian journal of endocrinology and metabolism* 17:665.

Kwon Y-M, Oh S-W, Hwang S-s, Lee C, Kwon H and Chung GE. (2012). Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. *The American journal of gastroenterology* 107:1852.

Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimecki WT and Cherrington NJ. (2013). The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. *Toxicological sciences* 137:26-35.

Larter CZ and Farrell GC. (2006). Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? *Journal of hepatology* 44:253-261.

Lau A, Whitman SA, Jaramillo MC and Zhang DD. (2013). Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. *Journal of biochemical and molecular toxicology* 27:99-105.

Lee B-S, Heo J, Kim Y-M, Shim SM, Pae H-O, Kim Y-M and Chung H-T. (2006). Carbon monoxide mediates heme oxygenase 1 induction via Nrf2 activation in hepatoma cells. *Biochemical and biophysical research communications* 343:965-972.

Lee WM. (2012). Acute liver failure. In: Editior, editor^editors. Seminars in respiratory and critical care medicine. Thieme Medical Publishers, 36-45.

Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern II TJ, Murray NG, McCashland T and Reisch JS. (2009). Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. *Gastroenterology* 137:856-864. e851.

Lee Y-M, Sutedja DS, Wai C-T, Dan Y-Y, Aung M-O, Zhou L, Cheng C-L, Wee A and Lim S-G. (2008). A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). *Hepatology international* 2:196-201.

Lehninger AL, Nelson DL, Cox MM and Cox MM. (2005). Lehninger principles of biochemistry. Macmillan.

Leroux A, Ferrere G, Godie V, Cailleux F, Renoud M-L, Gaudin F, Naveau S, Prévot S, Makhzami S and Perlemuter G. (2012). Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. *Journal of hepatology* 57:141-149.

Leung L, Kwong M, Hou S, Lee C and Chan JY. (2003). Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress. *Journal of Biological Chemistry* 278:48021-48029.

Lewis JR and Mohanty SR. (2010). Nonalcoholic fatty liver disease: a review and update. *Digestive diseases and sciences* 55:560-578.

Li S, Wang W, Niu T, Wang H, Li B, Shao L, Lai Y, Li H, Janicki JS and Wang XL. (2014). Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction. *Oxidative medicine and cellular longevity* 2014.

Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM, Kleemann R and van den Hoek AM. (2014). Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. *PloS one* 9:e115922.

Liu J, Li C, Waalkes MP, Clark J, Myers P, Saavedra JE and Keefer LK. (2003). The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. *Hepatology* 37:324-333.

Liu W, Wang D, Liu K and Sun X. (2012). Nrf2 as a converging node for cellular signaling pathways of gasotransmitters. *Medical hypotheses* 79:308-310.

Locatelli I, Sutti S, Vacchiano M, Bozzola C and Albano E. (2013). NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. *Clinical science* 124:279-287.

Lonardo A, Byrne C, Caldwell S, Cortez-Pinto H and Targher G. (2016). Global epidemiology of non-alcoholic fatty liver disease. Meta-analytic assessment of prevalence, incidence and outcomes. *Hepatology* 64:1388-1389.

Love S, Mudasir MA, Bhardwaj SC, Singh G and Tasduq SA. (2017). Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis. *Oncotarget* 8:113403.

Ludwig J, Viggiano TR, Mcgill DB and Oh B. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. In: Editior, editor^editors. Mayo Clinic Proceedings. 434-438.

Ma Q. (2013). Role of nrf2 in oxidative stress and toxicity. *Annual review of pharmacology and toxicology* 53:401-426.

Mangano K, Cavalli E, Mammana S, Basile MS, Caltabiano R, Pesce A, Puleo S, Atanasov AG, Magro G and Nicoletti F. (2018). Involvement of the Nrf2/HO-1/CO axis and therapeutic intervention with the CO-releasing molecule CORM-A1, in a murine model of autoimmune hepatitis. *Journal of cellular physiology* 233:4156-4165.

Mani M, Khaghani S, Mohammadi TG, Zamani Z, Azadmanesh K, Meshkani R, Pasalar P and Mostafavi E. (2013). Activation of Nrf2-antioxidant response element mediated glutamate cysteine ligase expression in hepatoma cell line by homocysteine. *Hepatitis monthly* 13.

Mann BE. (2010). Carbon monoxide: an essential signalling molecule. In: Editior, editor^editors. Medicinal Organometallic Chemistry. Springer, 247-285.

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D and Vierling JM. (2010). Diagnosis and management of autoimmune hepatitis. *Hepatology* 51:2193-2213.

Mantzaris MD, Tsianos EV and Galaris D. (2011). Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells. *The FEBS journal* 278:519-530.

Martius G, Alwahsh SM, Rave-Fränk M, Hess CF, Christiansen H, Ramadori G and Malik IA. (2014). Hepatic fat accumulation and regulation of FAT/CD36: an effect of hepatic irradiation. *International journal of clinical and experimental pathology* 7:5379.

Matsumoto H, Ishikawa K, Itabe H and Maruyama Y. (2006). Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. *Molecular and cellular biochemistry* 291:21-28.

McGill MR, Lebofsky M, Norris H-RK, Slawson MH, Bajt ML, Xie Y, Williams CD, Wilkins DG, Rollins DE and Jaeschke H. (2013). Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose–response, mechanisms, and clinical implications. *Toxicology and applied pharmacology* 269:240-249.

Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B and Aspichueta P. (2011). Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. *Gut* 60:1394-1402.

Mizuguchi S, Stephen J, Dencev-Bihari R, Markovic N, Suehiro S, Capretta F, Potter R and Cepinskas G. (2009). CO-releasing molecule (CORM-3)-derived CO

modulates neutrophil (PMN) migration across vascular endothelium by reducing the levels of cell surface-bound elastase. *Am J Physiol Heart Circ Physiol* 297:H920-H929.

Moi P, Chan K, Asunis I, Cao A and Kan YW. (1994). Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proceedings of the National Academy of Sciences of the United States of America* 91:9926-9930.

Morsy MA, Ibrahim SA, Abdelwahab SA, Zedan MZ and Elbitar HI. (2010). Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice. *Life sciences* 87:692-698.

Motterlini R. (2007). Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. In: Editior, editor^editors. Portland Press Limited.

Motterlini R, Foresti R and Green CJ. (2002). Studies on the development of carbon monoxide-releasing molecules: potential applications for the treatment of cardiovascular dysfunction. *Carbon Monoxide and Cardiovascular Functions*:249-271.

Motterlini R and Otterbein LE. (2010). The therapeutic potential of carbon monoxide. *Nature reviews Drug discovery* 9:728.

Motterlini R, Sawle P, Hammad J, Bains S, Alberto R, Foresti R and Green CJ. (2005). CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. *The FASEB journal* 19:284-286.

Mukhra R, Kaur T, Krishan K and Kanchan T. (2018). Overweight and Obesity: A major concern for health in India. *La Clinica Terapeutica* 169:e199-e201.

Muriel P and Gordillo KR. (2016). Role of oxidative stress in liver health and disease. *Oxidative Medicine and Cellular Longevity* 2016.

Nakajima K. (2012). Multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease. *International journal of hepatology* 2012.

Nakamoto K, Takayama F, Mankura M, Hidaka Y, Egashira T, Ogino T, Kawasaki H and Mori A. (2009). Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis. *Journal of clinical biochemistry and nutrition* 44:239-246.

Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, Noda H, Nabemoto S, Kurita S, Ota T and Ando H. (2009). Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. *Journal of Biological Chemistry* 284:14809-14818.

Nakao A, Choi AM and Murase N. (2006). Protective effect of carbon monoxide in transplantation. *Journal of cellular and molecular medicine* 10:650-671.

Narce M, Bellenger J, Rialland M and Bellenger S. (2012). Recent advances on stearoyl-Coa desaturase regulation in fatty liver diseases. *Current drug metabolism* 13:1454-1463.

Network TI. (2010). A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. *Clinical Toxicology* 48:424-430.

Neuschwander-Tetri BA and Caldwell SH. (2003). Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 37:1202-1219.

Nikolic I, Saksida T, Vujicic M, Stojanovic I and Stosic-Grujicic S. (2015). Anti-diabetic actions of carbon monoxide-releasing molecule (CORM)-A1: Immunomodulation and regeneration of islet beta cells. *Immunology letters* 165:39-46.

Nishikawa T, Bellance N, Damm A, Bing H, Zhu Z, Handa K, Yovchev MI, Sehgal V, Moss TJ and Oertel M. (2014). A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. *Journal of hepatology* 60:1203-1211.

Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K and Itoh Y. (2015). Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. *Journal of gastroenterology* 50:95-108.

Nourjah P, Ahmad SR, Karwoski C and Willy M. (2006). Estimates of acetaminophen (paracetomal)-associated overdoses in the United States. *Pharmacoepidemiology and drug safety* 15:398-405.

Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN and Csizmadia E. (2003). Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. *Nature medicine* 9:183.

Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, Epiphanio S, Chora Â, Rodrigues CD, Gregoire IP and Cunha-Rodrigues M. (2007). Heme oxygenase-1 and carbon

monoxide suppress the pathogenesis of experimental cerebral malaria. *Nature medicine* 13:703.

Pappachan JM, Babu S, Krishnan B and Ravindran NC. (2017). Non-alcoholic fatty liver disease: a clinical update. *Journal of clinical and translational hepatology* 5:384.

Pérez-Carreras M, Del Hoyo P, Martın MA, Rubio JC, Martın A, Castellano G, Colina F, Arenas J and Solis-Herruzo JA. (2003). Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. *Hepatology* 38:999-1007.

Pessayre D. (2007). Role of mitochondria in non-alcoholic fatty liver disease. *Journal of gastroenterology and hepatology* 22:S20-S27.

Pessayre D and Fromenty B. (2005). NASH: a mitochondrial disease. *Journal of hepatology* 42:928-940.

Piantadosi CA. (2002). Biological chemistry of carbon monoxide. *Antioxidants and Redox Signaling* 4:259-270.

Piantadosi CA, Carraway MS, Babiker A and Suliman HB. (2008). Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. *Circulation research* 103:1232-1240.

Pineau L, Colas J, Dupont S, Beney L, Fleurat-Lessard P, Berjeaud JM, Bergès T and Ferreira T. (2009). Lipid-induced ER stress: synergistic effects of sterols and saturated fatty acids. *Traffic* 10:673-690.

Pohjoismäki JL, Wanrooij S, Hyvärinen AK, Goffart S, Holt IJ, Spelbrink JN and Jacobs HT. (2006). Alterations to the expression level of mitochondrial transcription factor A, TFAM, modify the mode of mitochondrial DNA replication in cultured human cells. *Nucleic acids research* 34:5815-5828.

Poirier H, Degrace P, Niot I, Bernard A and Besnard P. (1996). Localization and Regulation of the Putative Membrane Fatty-Acid Transporter (FAT) in the Small Intestine: Comparison with Fatty Acid-Binding Proteins (FABP). *European journal of biochemistry* 238:368-373.

Poss KD and Tonegawa S. (1997). Reduced stress defense in heme oxygenase 1-deficient cells. *Proceedings of the National Academy of Sciences* 94:10925-10930.

Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X and Li X. (2009). Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. *Cell metabolism* 9:327-338.

Qi Z, Ci X, Huang J, Liu Q, Yu Q, Zhou J and Deng X. (2017). Asiatic acid enhances Nrf2 signaling to protect HepG2 cells from oxidative damage through Akt and ERK activation. *Biomedicine & Pharmacotherapy* 88:252-259.

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M and Caldwell S. (2016). Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. *Gastroenterology* 150:1147-1159. e1145.

Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, Lee WM and Group ALFS. (2016). Determinants of outcome among patients with acute liver failure listed for liver transplantation in the U nited S tates. *Liver Transplantation* 22:505-515.

Reddy SP. (2008a). The antioxidant response element and oxidative stress modifiers in airway diseases. *Current molecular medicine* 8:376-383.

Reddy SP. (2008b). The antioxidant response element and oxidative stress modifiers in airway diseases. *Current molecular medicine* 8:376-383.

Reisman SA, Csanaky IL, Aleksunes LM and Klaassen CD. (2009). Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. *Toxicological Sciences* 109:31-40.

Romao CC, Blättler WA, Seixas JD and Bernardes GJ. (2012). Developing drug molecules for therapy with carbon monoxide. *Chemical Society Reviews* 41:3571-3583.

Ruiz-Ramírez A, López-Acosta O, Barrios-Maya MA and El-Hafidi M. (2016). Cell death and heart failure in obesity: role of uncoupling proteins. *Oxidative medicine and cellular longevity* 2016.

Ryter SW, Alam J and Choi AM. (2006). Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiological reviews* 86:583-650.

Saito C, Lemasters JJ and Jaeschke H. (2010). c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity. *Toxicology and applied pharmacology* 246:8-17.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J and Unalp A. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *New England Journal of Medicine* 362:1675-1685.

Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ and Motterlini R. (2005). Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264. 7 murine macrophages. *British journal of pharmacology* 145:800-810.

Scarpulla RC. (2011). Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* 1813:1269-1278.

Schneider AL, Lazo M, Selvin E and Clark JM. (2014). Racial differences in nonalcoholic fatty liver disease in the US population. *Obesity* 22:292-299.

Shen W, Liu K, Tian C, Yang L, Li X, Ren J, Packer L, Cotman C and Liu J. (2008). R-α-Lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes. *Diabetologia* 51:165-174.

Sherif ZA, Saeed A, Ghavimi S, Nouraie S-M, Laiyemo AO, Brim H and Ashktorab H. (2016). Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations. *Digestive diseases and sciences* 61:1214-1225.

Singal AK, Jampana SC and Weinman SA. (2011). Antioxidants as therapeutic agents for liver disease. *Liver International* 31:1432-1448.

Slebos D-J, Ryter SW and Choi AM. (2003). Heme oxygenase-1 and carbon monoxide in pulmonary medicine. *Respiratory research* 4:7.

Sohn JH, Han K-L, Lee S-H and Hwang J-K. (2005). Protective effects of panduratin A against oxidative damage of tert-butylhydroperoxide in human HepG2 cells. *Biological and Pharmaceutical Bulletin* 28:1083-1086.

Suliman HB and Piantadosi CA. (2016). Mitochondrial quality control as a therapeutic target. *Pharmacological reviews* 68:20-48.

Svegliati Baroni G, D'Ambrosio L, Ferretti G, Casini A, Di Sario A, Salzano R, Ridolfi F, Saccomanno S, Jezequel AM and Benedetti A. (1998). Fibrogenic effect of oxidative stress on rat hepatic stellate cells. *Hepatology* 27:720-726.

Swanton E and Bulleid NJ. (2003). Protein folding and translocation across the endoplasmic reticulum membrane. *Molecular membrane biology* 20:99-104.

Szabó C. (2007). Hydrogen sulphide and its therapeutic potential. *Nature reviews Drug discovery* 6:917.

Szegezdi E, Logue SE, Gorman AM and Samali A. (2006). Mediators of endoplasmic reticulum stress-induced apoptosis. *EMBO reports* 7:880-885.

Takahashi Y, Soejima Y and Fukusato T. (2012). Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World journal of gastroenterology: WJG* 18:2300.

Takaki A, Kawai D and Yamamoto K. (2013). Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). *International journal of molecular sciences* 14:20704-20728.

Tanaka N and Aoyama T. (2006). PPAR and NASH. *Nihon rinsho Japanese journal of clinical medicine* 64:1089-1094.

Tang W, Jiang Y-F, Ponnusamy M and Diallo M. (2014). Role of Nrf2 in chronic liver disease. *World Journal of Gastroenterology: WJG* 20:13079.

Tanito M, Agbaga M-P and Anderson RE. (2007). Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal neuroprotection in vivo and in vitro. *Free Radical Biology and Medicine* 42:1838-1850.

Tariq Z, Green CJ and Hodson L. (2014). Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? *Liver International* 34:e180-e190.

Tilg H and Moschen AR. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 52:1836-1846.

Tiniakos DG, Vos MB and Brunt EM. (2010). Nonalcoholic fatty liver disease: pathology and pathogenesis. *Annual Review of Pathological Mechanical Disease* 5:145-171.

Tsukamoto H. (2002). Redox regulation of cytokine expression in Kupffer cells. *Antioxidants and Redox Signaling* 4:741-748.

Uchiyama S, Shimizu T and Shirasawa T. (2006). CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. *Journal of Biological Chemistry* 281:31713-31719.

Upadhyay KK, Jadeja RN, Thadani JM, Joshi A, Vohra A, Mevada V, Patel R, Khurana S and Devkar RV. (2018). Carbon monoxide releasing molecule A-1 attenuates acetaminophen-mediated hepatotoxicity and improves survival of mice by induction of Nrf2 and related genes. *Toxicology and applied pharmacology* 360:99-108.

Urquhart P, Rosignoli G, Cooper D, Motterlini R and Perretti M. (2007). Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. *Journal of Pharmacology and Experimental Therapeutics* 321:656-662.

Urrunaga NH, Jadeja RN, Rachakonda V, Ahmad D, McLean LP, Cheng K, Shah V, Twaddell WS, Raufman J-P and Khurana S. (2015). M1 muscarinic receptors modify oxidative stress response to acetaminophen-induced acute liver injury. *Free Radical Biology and Medicine* 78:66-81.

Van den Berg PA, Feenstra KA, Mark AE, Berendsen HJ and Visser AJ. (2002). Dynamic conformations of flavin adenine dinucleotide: simulated molecular dynamics of the

flavin cofactor related to the time-resolved fluorescence characteristics. *The Journal of Physical Chemistry B* 106:8858-8869.

van der Windt DJ, Sud V, Zhang H, Tsung A and Huang H. (2018). The effects of physical exercise on fatty liver disease. *Gene Expression, The Journal of Liver Research* 18:89-101.

Van Herpen N and Schrauwen-Hinderling V. (2008). Lipid accumulation in non-adipose tissue and lipotoxicity. *Physiology & behavior* 94:231-241.

Varadi J, Lekli I, Juhasz B, Bacskay I, Szabo G, Gesztelyi R, Szendrei L, Varga E, Bak I and Foresti R. (2007). Beneficial effects of carbon monoxide-releasing molecules on post-ischemic myocardial recovery. *Life sciences* 80:1619-1626.

Vitaglione P, Morisco F, Caporaso N and Fogliano V. (2005). Dietary antioxidant compounds and liver health. *Critical reviews in food science and nutrition* 44:575-586.

Voet D, Voet JG and Pratt CW. (1999). Fundamentals of biochemistry. Wiley New York.

Wallace DC. (2012). Mitochondria and cancer. *Nature Reviews Cancer* 12:685.

Wanders R, Vreken P, Den Boer M, Wijburg F, Van Gennip A and IJlst L. (1999). Disorders of mitochondrial fatty acyl-CoA β-oxidation. *Journal of inherited metabolic disease* 22:442-487.

Watkins M. (2010). Nitric Oxide–Dependent Bone Marrow Progenitor Mobilization by Carbon Monoxide Enhances Endothelial Repair After Vascular Injury Wegiel B, Gallo DJ, Raman KG, et al (Beth Israel Deaconess Med Ctr, Boston, MA; Univ of Pittsburgh School of Medicine, PA; Alfama Inc, Beverly, MA; et al) Circulation 121: 537-548, 2010. *Year Book of Vascular Surgery* 2010:12-13.

Weisiger R, Gollan J and Ockner R. (1981). Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances. *Science* 211:1048-1051.

Whyte IM, Francis B and Dawson AH. (2007). Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database. *Current medical research and opinion* 23:2359-2368.

Willy JA, Young SK, Stevens JL, Masuoka HC and Wek RC. (2015). CHOP links endoplasmic reticulum stress to NF-κB activation in the pathogenesis of nonalcoholic steatohepatitis. *Molecular biology of the cell* 26:2190-2204.

Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M and Weiss EJ. (2015). Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. *Endocrinology* 157:570-585.

Winkel AF, Engel CK, Margerie D, Kannt A, Szillat H, Glombik H, Kallus C, Ruf S, Güssregen S and Riedel J. (2015). Characterization of RA839, a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signaling. *Journal of Biological Chemistry* 290:28446-28455.

Woolbright BL and Jaeschke H. (2017). The impact of sterile inflammation in acute liver injury. *Journal of clinical and translational research* 3:170.

Wu KC, Cui JY and Klaassen CD. (2011). Beneficial role of Nrf2 in regulating NADPH generation and consumption. *Toxicological Sciences* 123:590-600.

Wu KC, Liu J and Klaassen CD. (2012). Role of Nrf2 in preventing ethanol-induced oxidative stress and lipid accumulation. *Toxicology and applied pharmacology* 262:321-329.

Wu L and Wang R. (2005). Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. *Pharmacological reviews* 57:585-630.

Yan F, Zhang Q-Y, Jiao L, Han T, Zhang H, Qin L-P and Khalid R. (2009). Synergistic hepatoprotective effect of Schisandrae lignans with Astragalus polysaccharides on chronic liver injury in rats. *Phytomedicine* 16:805-813.

Yin X, Zheng F, Pan Q, Zhang S, Yu D, Xu Z and Li H. (2015). Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening. *Journal of molecular endocrinology* 55:169-181.

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J and Bugianesi E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nature reviews Gastroenterology & hepatology* 15:11.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M. (2016). Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 64:73-84.

Yuan L and Kaplowitz N. (2009). Glutathione in liver diseases and hepatotoxicity. *Molecular aspects of medicine* 30:29-41.

Zangar RC, Davydov DR and Verma S. (2004). Mechanisms that regulate production of reactive oxygen species by cytochrome P450. *Toxicology and applied pharmacology* 199:316-331.

Zhang X-Q, Xu C-F, Yu C-H, Chen W-X and Li Y-M. (2014). Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. *World journal of gastroenterology: WJG* 20:1768.

Zhang Y, Yang X, Shi H, Dong L and Bai J. (2011). Effect of α-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes. *Lipids in health and disease* 10:122.

Zhao X, Cong X, Zheng L, Xu L, Yin L and Peng J. (2012). Dioscin, a natural steroid saponin, shows remarkable protective effect against acetaminophen-induced liver damage in vitro and in vivo. *Toxicology letters* 214:69-80.

Zheng L, Zhou Z, Lin L, Alber S, Watkins S, Kaminski N, Choi AM and Morse D. (2009). Carbon Monoxide Modulates α–Smooth Muscle Actin and Small Proline Rich-1a Expression in Fibrosis. *American journal of respiratory cell and molecular biology* 41:85-92.

Zhu R, Wang Y, Zhang L and Guo Q. (2012). Oxidative stress and liver disease. *Hepatology Research* 42:741-749.

Zimmermann A, Leffler CW, Tcheranova D, Fedinec AL and Parfenova H. (2007). Cerebroprotective effects of the CO-releasing molecule CORM-A1 against seizure-induced neonatal vascular injury. *American Journal of Physiology-Heart and Circulatory Physiology* 293:H2501-H2507.

Zuckerbraun BS, Billiar TR, Otterbein SL, Kim PK, Liu F, Choi AM, Bach FH and Otterbein LE. (2003). Carbon monoxide protects against liver failure through nitric oxide–induced heme oxygenase 1. *Journal of Experimental Medicine* 198:1707-1716.

Zuckerbraun BS, Chin BY, Bilban M, de Costa d'Avila J, Rao J, Billiar TR and Otterbein LE. (2007). Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. *The FASEB Journal* 21:1099-1106.